Pharmacodynamic Comparison of Prasugrel Versus Ticagrelor in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease | Zendy

Francesco Franchi | Zendy; Fabiana Rollini | Zendy; Niti R. Aggarwal | Zendy; Jenny Hu | Zendy; Megha Kureti | Zendy; Ashwin Durairaj | Zendy; Valeria E. Duarte | Zendy; Jung Rae Cho | Zendy; Latonya Been | Zendy; Martin M. Zenni | Zendy; Theodore A. Bass | Zendy; Dominick J. Angiolillo | Zendy

Open Access

Pharmacodynamic Comparison of Prasugrel Versus Ticagrelor in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease

Author(s) -

Francesco Franchi,

Fabiana Rollini,

Niti R. Aggarwal,

Jenny Hu,

Megha Kureti,

Ashwin Durairaj,

Valeria E. Duarte,

Jung Rae Cho,

Latonya Been,

Martin M. Zenni,

Theodore A. Bass,

Dominick J. Angiolillo

Publication year - 2016

Publication title -

circulation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 7.795

H-Index - 607

eISSN - 1524-4539

pISSN - 0009-7322

DOI - 10.1161/circulationaha.116.023402

Subject(s) - prasugrel , ticagrelor , medicine , clopidogrel , p2y12 , pharmacodynamics , coronary artery disease , aspirin , diabetes mellitus , pharmacology , cardiology , endocrinology , pharmacokinetics

Patients with diabetes mellitus (DM) are at increased risk of atherothrombotic events, underscoring the importance of effective platelet inhibiting therapies. Prasugrel and ticagrelor reduce thrombotic complications to a greater extent than clopidogrel. Subgroup analyses of pivotal clinical trials testing prasugrel and ticagrelor versus clopidogrel showed DM patients to have benefits that were consistent with the overall trial populations, although the magnitude of the ischemic risk reduction appeared to be enhanced with prasugrel. Whether these findings may be attributed to differences in the pharmacodynamic profiles of these drugs in DM patients remains poorly explored and represented the aim of this study.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research